通过新型干粉吸入器给药的二丙酸倍氯米松/富马酸福莫特罗在中国健康志愿者中的药代动力学特征。

IF 2.8 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Zhu Luo , Germano Lucci , Luigi Santoro , Eva Topole , Fabrizia Mariotti
{"title":"通过新型干粉吸入器给药的二丙酸倍氯米松/富马酸福莫特罗在中国健康志愿者中的药代动力学特征。","authors":"Zhu Luo ,&nbsp;Germano Lucci ,&nbsp;Luigi Santoro ,&nbsp;Eva Topole ,&nbsp;Fabrizia Mariotti","doi":"10.1016/j.pupt.2022.102129","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>An extrafine formulation of the inhaled corticosteroid beclometasone dipropionate (BDP) plus the long-acting β<sub>2</sub>-agonist formoterol fumarate (FF) has been available for years via a pressurised metered-dose inhaler for the management of asthma and chronic obstructive pulmonary disease. More recently, the same extrafine BDP/FF formulation has become available in a multidose dry-powder inhaler (DPI) called the NEXThaler. The pharmacokinetics (PK) of BDP/FF via this DPI have previously been evaluated in a Caucasian population. The current study aimed to evaluate the PK profile of BDP/FF via DPI in healthy Chinese volunteers. The results were then compared to previous Caucasian data.</p></div><div><h3>Methods</h3><p>This open-label parallel group study randomised subjects to single-dose BDP/FF 200/12, 400/24, or 800/48 μg via DPI. Blood samples were taken up to 24 h post-dose for PK evaluation of BDP, beclometasone 17-monopropionate (B17MP, active metabolite of BDP) and formoterol. The primary objective of the study was to evaluate the PK of BDP/FF (BDP, B17MP and formoterol). The study is registered on the World Health Organization International Clinical Trials Registry Platform (ChiCTR1900021899).</p></div><div><h3>Results</h3><p>Of 36 subjects randomised, all completed the study. Following inhalation of all three doses, plasma concentration of formoterol and BDP increased rapidly, with peak mean values at the first post-dose timepoint (5 min), then rapidly decreasing; B17MP reached peak concentration slightly later. Plasma exposure to formoterol, BDP and B17MP increased broadly in a dose-proportional manner to BDP/FF dose, with t<sub>max</sub> values similar across the dose range. All BDP/FF doses were generally well tolerated.</p></div><div><h3>Conclusions</h3><p>Therapeutic and supra-therapeutic doses of BDP/FF administered via DPI resulted in approximately dose-proportional plasma exposure in healthy Chinese subjects, with PK profiles that were comparable to previous data from Caucasian subjects.</p></div>","PeriodicalId":20799,"journal":{"name":"Pulmonary pharmacology & therapeutics","volume":"73 ","pages":"Article 102129"},"PeriodicalIF":2.8000,"publicationDate":"2022-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1094553922000207/pdfft?md5=fee1920c173b40823cfecc203b5cd23b&pid=1-s2.0-S1094553922000207-main.pdf","citationCount":"1","resultStr":"{\"title\":\"Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers\",\"authors\":\"Zhu Luo ,&nbsp;Germano Lucci ,&nbsp;Luigi Santoro ,&nbsp;Eva Topole ,&nbsp;Fabrizia Mariotti\",\"doi\":\"10.1016/j.pupt.2022.102129\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Introduction</h3><p>An extrafine formulation of the inhaled corticosteroid beclometasone dipropionate (BDP) plus the long-acting β<sub>2</sub>-agonist formoterol fumarate (FF) has been available for years via a pressurised metered-dose inhaler for the management of asthma and chronic obstructive pulmonary disease. More recently, the same extrafine BDP/FF formulation has become available in a multidose dry-powder inhaler (DPI) called the NEXThaler. The pharmacokinetics (PK) of BDP/FF via this DPI have previously been evaluated in a Caucasian population. The current study aimed to evaluate the PK profile of BDP/FF via DPI in healthy Chinese volunteers. The results were then compared to previous Caucasian data.</p></div><div><h3>Methods</h3><p>This open-label parallel group study randomised subjects to single-dose BDP/FF 200/12, 400/24, or 800/48 μg via DPI. Blood samples were taken up to 24 h post-dose for PK evaluation of BDP, beclometasone 17-monopropionate (B17MP, active metabolite of BDP) and formoterol. The primary objective of the study was to evaluate the PK of BDP/FF (BDP, B17MP and formoterol). The study is registered on the World Health Organization International Clinical Trials Registry Platform (ChiCTR1900021899).</p></div><div><h3>Results</h3><p>Of 36 subjects randomised, all completed the study. Following inhalation of all three doses, plasma concentration of formoterol and BDP increased rapidly, with peak mean values at the first post-dose timepoint (5 min), then rapidly decreasing; B17MP reached peak concentration slightly later. Plasma exposure to formoterol, BDP and B17MP increased broadly in a dose-proportional manner to BDP/FF dose, with t<sub>max</sub> values similar across the dose range. All BDP/FF doses were generally well tolerated.</p></div><div><h3>Conclusions</h3><p>Therapeutic and supra-therapeutic doses of BDP/FF administered via DPI resulted in approximately dose-proportional plasma exposure in healthy Chinese subjects, with PK profiles that were comparable to previous data from Caucasian subjects.</p></div>\",\"PeriodicalId\":20799,\"journal\":{\"name\":\"Pulmonary pharmacology & therapeutics\",\"volume\":\"73 \",\"pages\":\"Article 102129\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2022-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S1094553922000207/pdfft?md5=fee1920c173b40823cfecc203b5cd23b&pid=1-s2.0-S1094553922000207-main.pdf\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pulmonary pharmacology & therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S1094553922000207\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pulmonary pharmacology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1094553922000207","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 1

摘要

一种吸入皮质类固醇二丙酸倍氯米松(BDP)加长效β2激动剂富马酸福莫特罗(FF)的精制制剂已通过加压计量吸入器用于治疗哮喘和慢性阻塞性肺疾病多年。最近,在一种名为NEXThaler的多剂量干粉吸入器(DPI)中,也可以使用相同的外精制BDP/FF配方。BDP/FF的药代动力学(PK)已经通过DPI在高加索人群中进行了评估。本研究旨在通过DPI评估中国健康志愿者BDP/FF的PK谱。然后将结果与之前的高加索数据进行比较。方法采用开放标签平行组研究,通过DPI将受试者随机分为单剂量BDP/FF 200/12、400/24或800/48 μg。给药后24小时采血,对BDP、17-单丙酸倍氯米松(B17MP, BDP的活性代谢物)和福莫特罗进行PK评价。本研究的主要目的是评估BDP/FF (BDP, B17MP和福莫特罗)的PK。该研究已在世界卫生组织国际临床试验注册平台(ChiCTR1900021899)注册。结果36名随机受试者全部完成了研究。吸入所有三种剂量后,福莫特罗和BDP血浆浓度迅速升高,在第一个给药后时间点(5 min)达到峰值,然后迅速下降;B17MP达到峰值浓度稍晚。血浆暴露于福莫特罗、BDP和B17MP与BDP/FF剂量呈剂量正比关系,tmax值在整个剂量范围内相似。所有BDP/FF剂量通常耐受良好。结论:通过DPI给药的治疗和超治疗剂量BDP/FF导致健康中国受试者的血浆暴露与剂量成正比,其PK谱与先前来自高加索受试者的数据相当。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers

Introduction

An extrafine formulation of the inhaled corticosteroid beclometasone dipropionate (BDP) plus the long-acting β2-agonist formoterol fumarate (FF) has been available for years via a pressurised metered-dose inhaler for the management of asthma and chronic obstructive pulmonary disease. More recently, the same extrafine BDP/FF formulation has become available in a multidose dry-powder inhaler (DPI) called the NEXThaler. The pharmacokinetics (PK) of BDP/FF via this DPI have previously been evaluated in a Caucasian population. The current study aimed to evaluate the PK profile of BDP/FF via DPI in healthy Chinese volunteers. The results were then compared to previous Caucasian data.

Methods

This open-label parallel group study randomised subjects to single-dose BDP/FF 200/12, 400/24, or 800/48 μg via DPI. Blood samples were taken up to 24 h post-dose for PK evaluation of BDP, beclometasone 17-monopropionate (B17MP, active metabolite of BDP) and formoterol. The primary objective of the study was to evaluate the PK of BDP/FF (BDP, B17MP and formoterol). The study is registered on the World Health Organization International Clinical Trials Registry Platform (ChiCTR1900021899).

Results

Of 36 subjects randomised, all completed the study. Following inhalation of all three doses, plasma concentration of formoterol and BDP increased rapidly, with peak mean values at the first post-dose timepoint (5 min), then rapidly decreasing; B17MP reached peak concentration slightly later. Plasma exposure to formoterol, BDP and B17MP increased broadly in a dose-proportional manner to BDP/FF dose, with tmax values similar across the dose range. All BDP/FF doses were generally well tolerated.

Conclusions

Therapeutic and supra-therapeutic doses of BDP/FF administered via DPI resulted in approximately dose-proportional plasma exposure in healthy Chinese subjects, with PK profiles that were comparable to previous data from Caucasian subjects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
6.20
自引率
0.00%
发文量
41
审稿时长
42 days
期刊介绍: Pulmonary Pharmacology and Therapeutics (formerly Pulmonary Pharmacology) is concerned with lung pharmacology from molecular to clinical aspects. The subject matter encompasses the major diseases of the lung including asthma, cystic fibrosis, pulmonary circulation, ARDS, carcinoma, bronchitis, emphysema and drug delivery. Laboratory and clinical research on man and animals will be considered including studies related to chemotherapy of cancer, tuberculosis and infection. In addition to original research papers the journal will include review articles and book reviews. Research Areas Include: • All major diseases of the lung • Physiology • Pathology • Drug delivery • Metabolism • Pulmonary Toxicology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信